Tosufloxacin Property

CAS DataBase Reference

108138-46-1(CAS DataBase Reference)

Hazard and Precautionary Statements (GHS)

Tosufloxacin Chemical Properties,Usage,Production

Uses

Tosufloxacin Tosilate (CAS# 100490-36-6) was identified in a Haemophilus influenza clone ST422.

Definition

ChEBI: 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid is a 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 3-aminopyrrolidin-1-yl substituents at positions 1, 6 and 7 respectively. It is a 1,8-naphthyridine derivative, an amino acid, a monocarboxylic acid, an organofluorine compound, an aminopyrrolidine, a tertiary amino compound, a primary amino compound and a quinolone antibiotic. It is a conjugate base of a 1-[6-carboxy-8-(2,4-difluorophenyl)-3-fluoro-5-oxo-5,8-dihydro-1,8-naphthyridin-2-yl]pyrrolidin-3-aminium.

brand name

Tosufloxacin Tosilate is JAN.

Pharmaceutical Applications

It is active against a wide range of Gram-positive and Gram-negative bacteria, including Acinetobacter spp., L. pneumophila and Campylobacter spp. Unlike many quinolones it is moderately active against L. monocytogenes. C. trachomatis is also moderately susceptible. It is active against some anaerobes, including the B. fragilis group. Activity against Mycobacterium spp. is limited. It is well absorbed by the oral route, achieving a plasma concentration of c. 1 mg/L 4 h after a 300 mg dose. Around 30–35% of the dose is eliminated in the urine, with an apparent elimination half-life of 6–7 h.
Clinical experience is limited, but high clinical and bacteriological cure rates have been obtained in patients with skin and soft-tissue infections.